All In Biotech

Free tool

FAERS Monitor: Olumiant

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 207924 or its brand name (Olumiant, Baricitinib). Reports on generic versions are filed under their own applications.

Reports

9,777

Serious

6,825

70% of reports

Hospitalization

3,177

Death reported

891

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective786
  • off label use759
  • covid-19458
  • rheumatoid arthritis413
  • pulmonary embolism309
  • pneumonia285
  • headache269
  • herpes zoster243
  • death237
  • nausea237
  • deep vein thrombosis215
  • arthralgia191
  • fatigue190
  • condition aggravated189
  • weight increased187

Reports by year received

View as table
YearReports
20121
20131
20141
20152
20161
20178
2018314
20191,085
2020846
20211,574
20221,436
20231,654
20241,408
2025944
2026502

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,044,382 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
herpes zosterSignal2439.18.11,749
rheumatoid arthritisSignal4137.97.12,466
deep vein thrombosisSignal2157.16.31,128
pulmonary embolismSignal3097.06.31,590
covid-19Signal4585.65.11,748
pneumonia2851.91.7121
off label use7591.91.7317
weight increased1871.81.666
condition aggravated1891.31.216
drug ineffective7861.31.252
arthralgia1911.00.90
headache2690.90.82
nausea2370.60.648
death2370.60.569
fatigue1900.50.584

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.